Hyperpituitarism: Clinical Trials

2 trials for Hyperpituitarism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated. 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Terminated 2

Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Debio 4126, Sandostatin LAR, Somatuline ATG - Acromegaly, GEP-NET
Phase 1TerminatedDebiopharm International SA192022-05-182025-11-17
A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
ONO-5788, ONO-5788 Placebo, Octreotide - Acromegaly
Phase 1TerminatedOno Pharmaceutical Co., Ltd.762018-06-072019-06-05

Narrower conditions

Acromegaly (2)  ·  Gastro-enteropancreatic neuroendocrine tumor (1)

Broader conditions

Bone Diseases (2)  ·  Bone Diseases, Endocrine (2)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Endocrine System Diseases (2)  ·  Hypothalamic Diseases (2)  ·  Musculoskeletal Diseases (2)  ·  Nervous System Diseases (2)  ·  Pituitary Diseases (2)

Interventions

Octreotide (2)  ·  lanreotide (1)

Sponsors

Debiopharm International SA (1)  ·  Ono Pharmaceutical Co., Ltd. (1)

Countries

Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Terry O'Reilly, MD (1)